According to international guidelines and current literature, patients with luminal-like breast cancer (HER2 negative, ER+) could benefit from neoadjuvant endocrine therapy (14) as a safe and effective option that would allow them to temporarily delay surgery and outpatient visits. This evidence concerns the gene ERBB2 and breast carcinoma.